GlassScriptPhysician profile
Steven H Berger
NPI 1376504589
$2,135.85
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,518 · 2020: $107 · 2021: $35.35 · 2022: $475.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $603.61 | 2019-2020 | |
| Alkermes, INC. | $386.23 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $253.47 | 2019 | |
| Janssen Pharmaceuticals, INC | $222.56 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $222.28 | 2019-2022 | |
| Allergan, INC. | $203.03 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.45 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $55.64 | 2019 | |
| Indivior INC. | $50.17 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.41 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.